Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: Results of phase III trial ETV-027.

被引：0
|
作者：
Shouval, D
Lai, CL
Cheinquer, H
Lok, A
DeHertogh, D
Wilber, R
Cross, A
Zink, R
Fernandes, L
机构：
[1] Hadassah Hebrew Univ Hosp, Jerusalem, Israel
[2] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[3] Univ Fed Rio Grande Sul, Porto Alegre, RS, Brazil
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Univ Connecticut, Farmington, CT USA
[6] Bristol Myers Squibb Co, Pharmaceut Res Inst, Wallingford, CT 06492 USA
来源：
HEPATOLOGY | 2004年 / 40卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：728A / 728A
页数：1
相关论文
共 50 条
  • [41] Impact of Entecavir Versus Lamivudine on Hepatic Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-NaiVE HBeAg Positive Chronic Hepatitis B Patients
    Bowden, Scott
    Locarnini, Stephen
    Chang, Ting-Tsung
    Chao, You-Chen
    Han, Kwang-Hyub
    Gish, Robert G.
    De Man, Robert A.
    Llamoso, Cyril
    Tang, Hong
    GASTROENTEROLOGY, 2013, 144 (05) : S950 - S950
  • [42] Histologic Improvement in Asian Patients With HBeAg(+) and HBeAg(-) Chronic Hepatitis B After Long-Term Treatment With Entecavir: Results From ETV-022,-027 and-901 Studies
    Tong, Myron J.
    Chang, Ting-Tsung
    Wu, Shun-Sheng
    Han, Kwang-Hyub
    Yoon, Seung Kew
    Pan, Calvin
    Kowdley, Kris
    Hu, Ke-Qin
    Goodman, Zachary
    Beebe, Suzanne
    Iloeje, Uchenna H.
    Tang, Hong
    GASTROENTEROLOGY, 2010, 138 (05) : S793 - S793
  • [43] Impact of entecavir versus lamivudine on hepatic covalently closed-circular DNA and total hepatic HBV DNA in nucleoside-naive HBeAg-positive chronic hepatitis B patients
    Bowden, S.
    Locarnini, S.
    Chang, T. T.
    Chao, T. C.
    Han, K. H.
    Gish, R. G.
    De Man, R.
    Llamoso, C.
    Tang, H.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 153 - 153
  • [44] Polymorphism of estrogen receptor alpha (ESR1) is associated with virological response to entecavir (ETV) in nucleoside-naive adult patients with chronic hepatitis B
    Zhang, T. -T.
    Ye, J.
    Xia, S. -L.
    Zhang, Y. -F.
    Su, Q.
    Zhang, Z. -H.
    Li, X.
    INFECTION, 2013, 41 (02) : 371 - 378
  • [45] Entecavir (ETV) demonstrates consistent responses throughout baseline disease and demographic subgroups for the treatment of lamivudine-refractory HBeAg(+) patients with chronic hepatitis B
    Yurdaydin, C.
    Senturk, H.
    Boron-Kaczmarska, A.
    Raptopoulou-Gigi, M.
    Batur, Y.
    Goodman, Z.
    Vaughan, J.
    Brett-Smith, H.
    Hindes, R.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S190 - S191
  • [46] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    Sollano, J.
    De Man, R. A.
    Mutimer, D.
    Gish, R. G.
    Chang, T. -T.
    Zhu, J.
    Cross, A.
    Brett-Smith, H.
    LIVER INTERNATIONAL, 2006, 26 : 6 - 7
  • [47] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    De Man, R. A.
    Mutimer, D.
    Gish, R.
    Chang, T.
    Zhu, J.
    Cross, A.
    Brett-Smith, H.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S89 - S89
  • [48] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    Chang, Ting-Tsung
    Chao, You-Chen
    Sollano, Jose
    Han, Kwang-Hyub
    Lai, Ching-Lung
    Lao-Tan, Judy
    Akbar, Nurul
    Zhu, Jin
    Cross, Anne
    Brett-Smith, Helena
    Neo, Boon-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A89 - A89
  • [49] Entecavir (ETV) treatment through 96 weeks results in substantial virologic and biochemical improvement and HBeAg seroconversion in HBeAg(+) chronic hepatitis B (CHB) patients (study ETV-022)
    Chang, Ting-Tsung
    Chao, You-Chen
    Sollano, Jose
    Han, Kwang-Hyub
    Lai, Ching-Lung
    Lao-Tan, Judy
    Akbar, Nurul
    Zhu, Jin
    Cross, Anne
    Brett-Smith, Helena
    Neo, Boon-Leong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A33 - A33
  • [50] Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (study ETV-022)
    Gish, RG
    Chang, TT
    De Man, RA
    Gadano, A
    Sollano, J
    Han, K
    Lok, A
    Zhu, J
    Cross, A
    Brett-Smith, H
    Fernandes, L
    HEPATOLOGY, 2005, 42 (04) : 267A - 268A
12345